begin end vs end
share gener stagnant sinc
isnt particularli concern given stock outperform
market massiv amount sinc nearli note
recent downward shift sentiment much
deterior enthusiasm relat
ilmn fourth quarter confer call investor pick
novaseq placement shortfal
somewhat moder consum growth
soft revenu guid pessim consum
fine point help support view late
cycl novaseq turn valuat compress
clearli subscrib view whatsoev merit
analysi contempl end
follow piec address aforement main concern
offer rebutt still much earli cycl
least begin decad plu prolifer
technolog also argu histor concept product
cycl like longer hold given notabl deliber pivot
manag strategi commun remain
somewhat undetect investor broadli mind
longer boom bust equiti depend new box launch
categori winner consist compound-annual-growth-rate revenu
penetr massiv market may mean less volatil
abil make massiv return still place share
uniqu compani within healthcar complex ew
mayb materi higher risk reiter
outperform rate rais pt
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
nt worri novaseq shortfal end cycl hear concern
today merit histor saw moder year post new product launch
howev manag deliber novaseq launch talk extend adopt curv
sinc introduct make sens us manag learn prior mistak seek oversatur
suppli deliber price decis consum given far cost alreadi come
would also note novaseq come strongest ever placement new custom
still make box ship major workflow demand impli convers
 high throughput hiseq user also suggest custom like quit yet
convert mani remain box moder low throughput natur also make sens
offer notabl save origin recent price cut chip
intro prime favor love rapid run mode think next phase
convers occur exactli match manag commentari multi-year balanc
adopt curv furthermor underli util per box steadili upward trend posit sign
industri wide capac util vs prior end cycl util start dip instrument growth realli
tail would shock given huge uptick clinic applic bottom line fear critic total misplac
like good expect
didnt sequenc consum growth moder doesnt guid sound aggress
technic ye sequenc consum growth moder vs fy howev adjust
stock order prior year believ closer actual acceler doubl stack basi
despit materi challeng comp eas balanc look annual
basi growth averag past year past year see massiv emerg
opportun rugd pophealth oncolog solid growth nipt noth us suggest slow
bottom line fear critic total misplac like good expect
revenu guid soft isnt concern admit knew would touch
soft vs consensu expect turn bit wors expect said thought
underli assumpt total make sens us start point main driver sequenti declin
instrument come record box revenu w/ guid
basic put box revenu line w/ last prior given like slow burn convers hiseq
time uncertainti custom accept seem conserv prudent furthermor
manag also highlight pull forward chines stock order china still
ex stock also exagger impli sequenti declin albeit would note consum
still expect flat despit stock order guid slow ramp box place us
construct lastli also known headwind gel roll post ramp back
consum genom array guid msd hsd qoq yoy us like quit soft ex us better
us help later year put togeth think initi assumpt defend solid logic also
present behind acceler exagger vs prior year make sens given time
larg revenu event ultim think fy revenu beatabl achiev bottom line fear justifi
explain still think beat
consum genom market feel like cabbag patch much written materi
slowdown consum genet market albeit would note concern us centric
weak explain christma effect wherebi fad gift repeat also
like due busi model pivot player focus mine data drug trial
drive profit would note asia still appear grow materi expans applic
outsid genealog basic health also help long term remain bullish lt consum genom given area
like diet fit acknowledg near term like look ugli thank think captur
alreadi guid might modestli wors guid dont think enough move needl
materi bottom line fear justifi monitor
conclus concern worst case consum genom disappoint box line
need believ consum ramp hit fy guid feel seem pretti manag would
also note valuat line histor level rate growth thu weak would like
bought risk reward seem favor
major growth driver emerg clinic surpris part
convers one talk massiv inflect point sever key area growth first oldi
goodi term nipt today test perform us possibl alreadi
coverag assumpt growth seem feasibl add major develop europ
franc seem low would also point birth occur global price point may
high today see mother undergo nipt test see reason remain key driver growth
move rugd rare diseas patient global half children current take year
diagnos rare diseas mani case kid dont live past year old born one
peopl us cover per test rare diseas uk also highli focus expand sequenc
amongst patient group alreadi implement sequenc program rare diseas diagnosi might
small number assum growth remain highli elev
popseq also infanc gel uk move needl demand individu
project work israel saudi arabia turkey qatar bangladesh name mani
intend sequenc million franc intend sequenc peopl ramp year singapor
sequenc peopl anoth million via array also ramp year us
us per year year sequenc project ramp btw
help explain extrem season year
lastli would point oncolog patient exist today get tumor sequenc
move massiv mention ton cdx possibl come well futur promis
earli stage cancer screen pull chart gh tell market isnt excit cancer orient
sequenc huugg presid say
conclus save week request luke killer model think debat
novaseq product cycl earli phase adopt life chang technolog realli go
call end dont think buy stock dip work last decad dont see
differ
valuat see share today ex helix dilut compar averag
year averag also long term averag thu vs histori particularli expens seem fair
even compound-annual-growth-rate ep growth seem pretti good spent
 common mistak st make credit futur platform product that tough
explain model alway growth slower year model know look
effect ep peak margin normal current set opportun would get us nearli
ep seem pretti reason would discount better growth anoth way
think valuat
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin march
analyst luke sergott ross muken primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
